- Home
- BNZI vs CDT Comparison
BNZI vs CDT Comparison
Compare BNZI & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- CDT
- Stock Information
- Founded
- BNZI 2016
- CDT 2019
- Country
- BNZI United States
- CDT United States
- Employees
- BNZI N/A
- CDT N/A
- Industry
- BNZI
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- BNZI
- CDT Health Care
- Exchange
- BNZI Nasdaq
- CDT Nasdaq
- Market Cap
- BNZI 11.5M
- CDT 2.2M
- IPO Year
- BNZI N/A
- CDT N/A
- Fundamental
- Price
- BNZI $4.16
- CDT $2.37
- Analyst Decision
- BNZI Strong Buy
- CDT
- Analyst Count
- BNZI 1
- CDT 0
- Target Price
- BNZI $24.00
- CDT N/A
- AVG Volume (30 Days)
- BNZI 481.0K
- CDT 475.8K
- Earning Date
- BNZI 08-13-2025
- CDT 08-11-2025
- Dividend Yield
- BNZI N/A
- CDT N/A
- EPS Growth
- BNZI N/A
- CDT N/A
- EPS
- BNZI N/A
- CDT N/A
- Revenue
- BNZI $6,827,490.00
- CDT N/A
- Revenue This Year
- BNZI $337.60
- CDT N/A
- Revenue Next Year
- BNZI $91.81
- CDT N/A
- P/E Ratio
- BNZI N/A
- CDT N/A
- Revenue Growth
- BNZI 52.95
- CDT N/A
- 52 Week Low
- BNZI $3.93
- CDT $2.21
- 52 Week High
- BNZI $112.00
- CDT $682.35
- Technical
- Relative Strength Index (RSI)
- BNZI 24.16
- CDT 34.66
- Support Level
- BNZI $4.11
- CDT $2.57
- Resistance Level
- BNZI $6.90
- CDT $2.93
- Average True Range (ATR)
- BNZI 0.69
- CDT 0.24
- MACD
- BNZI -0.10
- CDT 0.15
- Stochastic Oscillator
- BNZI 4.03
- CDT 23.81
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.